UNITED LABS.INTL.HDG. increases its risk exposure and slightly lowers to Neutral
UNITED LABS.INTL.HDG. (HK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date March 15, 2022, the closing price was HKD 3.47 and its expected value was estimated at HKD 4.36.The United Laboratories International Holdings is an investment holding company. Through its subsidiaries, Co. is engaged in the manufacturing and sale of pharmaceutical products Hong Kong, the manufacturing and sale of soft capsules casings and production and sale of organic fertilizer in the People's Republic of China, research and development of pharmaceutical intermediate products and trading of pharmaceutical products in India and Germany. Co.'s operations are organized into three business segments: sale of intermediate products; sale of bulk medicine; and sale of antibiotics finished products, non-antibiotics finished products and capsule casings.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.